Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTBK1 | Q5TCY1 | 11/20 | 0.64 |
| ▸ | TTBK2 | Q6IQ55 | 11/20 | 0.64 |
| ▸ | KDR | P35968 | 3/20 | 0.56 |
| ▸ | EGFR | P00533 | 2/20 | 0.56 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.48 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.46 |
| ▸ | IGF1R | P08069 | 1/20 | 0.46 |
| ▸ | SRC | P12931 | 1/20 | 0.46 |
| ▸ | TEK | Q02763 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17528585 | 0.81 | ADRA2A (0.53) | TTBK1TTBK2KDREGFRPDGFRB | |
| SCHEMBL19033752 | 0.81 | SYK (0.44) | TTBK1TTBK2KDREGFRPDGFRB | |
| SCHEMBL3108501 | 0.75 | NPY5R (0.72) | KDREGFRPDGFRBMEN1POLB | |
| SCHEMBL24881479 | 0.75 | TTBK1 (1.00) | TTBK1TTBK2 | |
| SCHEMBL5463564 | 0.73 | KMT2A (0.65) | KDREGFRPDGFRBMEN1POLB | |
| SCHEMBL12736495 | 0.73 | SYK (0.42) | TTBK1TTBK2KDREGFRPDGFRB | |
| SCHEMBL3121619 | 0.72 | KDR (0.64) | KDREGFRPDGFRBABCB1 | |
| SCHEMBL18540801 | 0.72 | TTK (0.47) | KDREGFRPDGFRBIGF1R | |
| SCHEMBL27393525 | 0.72 | DYRK1A (0.44) | TTBK1TTBK2 | |
| SCHEMBL31098989 | 0.71 | TTBK1 (0.64) | TTBK1TTBK2EGFRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170253612-A1 | PYRIMIDINE COMPOUNDS AND PYRIMIDO INDOLE COMPOUNDS AND METHODS OF USE | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2017-09-07 | — | — | US | disclosed |
| US-9688690-B2 | Pyrimidine compounds and pyrimido indole compounds and methods of use | DUQUESNE UNIVERSITY OF THE HOLY GHOST (US) | 2017-06-27 | — | — | US | disclosed |
| WO-2016022890-A1 | PYRIMIDINE COMPOUNDS AND PYRIMIDO INDOLE COMPOUNDS AND METHODS OF USE | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2016-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170253612-A1 | PYRIMIDINE COMPOUNDS AND PYRIMIDO INDOLE COMPOUNDS AND METHODS OF USE | DPYD, HPRT1, TPMT | TTBK1 2498/4885TTBK2 2277/4885KDR 3538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.